 |
 |
 |
|
|
||
|
|
Eloxatin |
|
Eloxatin is a third-generation, platinum-based anti-cancer agent! Acyline is a novel GnRH antagonist found in animal studies to be a potent suppressor of circulating gonadotropin and testosterone T ; levels. We conducted the first study of acyline administration to humans. Eight healthy, eugonadal young men were administered a series of acyline injections 0, 2.5, 7.5, 25, and 75 g kg ; , each injection separated by at least 10 d. Serum FSH, LH, and T levels were measured for 7 d after injections. Acyline suppressed FSH, LH, and T levels in a dosedependent fashion. Maximal suppression occurred after injection of 75 g acyline, which suppressed FSH to 46.9 2.5%, LH to 12.4 2.2%, and T to 13.4 1.4% of baseline levels, maintaining suppression for over 48 h. Serum acyline levels peaked at 1 h 18.9 0.9 ng ml, remained significantly elevated above background 7 d after injection, and returned to background levels by 14 17 after injection. Side-effects at the site of injection were limited to infrequent blush and pruritus that resolved within 90 min of injection. Higher doses of acyline might be effective as depot injections for long-lasting gonadotropin suppression in hormone-dependent diseases and for use in male hormonal contraception regimens. J Clin Endocrinol Metab 87: 32153220, 2002. Seromycin cycloserine cycloserine drug interactions compare cycloserine with other medications for the treatment of: tuberculosis - active , tuberculosis - extrapulmonary user reviews: 0 comment s ; about cycloserine services a to z drug list drugs by condition drug side effects pill identifier interactions checker news & articles new drug approvals new drug applications fda drug alerts clinical trial results drug image search patient care notes medical encyclopedia medical dictionary medical videos - drug classification community forums for professionals drug imprint codes medical abbreviations veterinary drugs contact us news feeds advertise here recent searches carisoprodol valium increlex rhophylac zerit enbrel viagra propecia lipitor xenical ephedrine protonix eloxatin rocephin klonopin duragesic vicoprofen recently approved pristiq arcalyst xyntha simcor accretropin moxatag tekturna hct intelence recothrom flo-pred more. DISCUSSION The contribution of committed progenitor cells to reconstitution of hematopoiesis after bone marrow and peripheral blood stem cell transplantation has been thought to be limited to early stages of engraftment. Studies have been reported supporting the concept of a correlation between. The sins of humanity generally 6: 5-8 The second reason for the flood was the sinfulness of humanity generally. 6: 5 Men's and women's actions were very wicked and their thoughts and affections were completely evil by this time cf. vv. 11-12; Rom. 1: 18-32 ; . "Near the turn of the 19th century F. W. Farrar wrote a book entitled Seekers After God. The book was a popular seller and was in considerable demand. A certain western bookseller had a number of requests for the volume but had no copies available. He sent a telegram to the dealers in New York requesting them to ship him a number of the. CORT presented long-term follow-up data on Oxaliplatin-treated colorectal cancer patients. Oxaliplatin Eloxatin ; is a new drug approved in 2003 for these patients. CORT was the only Dallas testing site for Oxaliplatin, dating back to 1999 in three major consecutive studies. Few other US Centers have lengthy follow-up data on the durability of treatment-induced remissions. This is the first of such reports and emend. 1. Bowers J. Medical Education in Japan. New York, NY: Harper & Row; 1965. 2. Eikoh M. Japan's encounter with Western medical science: "the beginning of Dutch study, " being the memoirs of an 18th century doctor. Bull Hist Med. 1959; 33: 315-329. Veith I. Physician travelers in Japan. JAMA. 1965; 192: 137-140. Kuowenhoven A, Forrer M. Siebold and Japan: His Life and Work. Leiden, the Netherlands: Hotei Publishing; 2000. 5. Dettlebacher W. Philipp Franz von Siebold's youth in Wurzburg 1796-1820 ; . In: Thiede A, Hiki Y, Keil G, eds. Philipp Franz von Siebold and His Era. Berlin, Germany: Springer Verlag; 2000: 63-70. 6. von Leers J. Der Japan-Siebold: Die Grossleistung eines deutschen Arztes. Dtsch Med Wochenschr. 1942; 68: 1151-1153. Miyasaka A. Philipp Franz von Siebold and his influence on the cultural development of Japan. In: Thiede A, Hiki Y, Keil G, eds. Philipp Franz von Siebold and His Era. Berlin, Germany: Springer Verlag; 2000: 95-99. 8. Beukers H. The Mission of Hippocrates in Japan: The Contribution of Philipp Franz von Siebold. Amsterdam, the Netherlands: Four Centuries of Netherlands-Japan Relations; 1998: 70-75. 9. von Siebold J. Philipp Franz von Siebold. Munich Med Wochenschr. 1941; 88: 1185-1186. Miyazaki M. Siebold's mydriatic eyedrops [in Japanese]. Yakugaku Zasshi. 1994; 29: 469-483. Komoto J. 150th Anniversary of Genseki Habu's birth. Nippon Ganka Gakkai Zasshi. 1919; 20-202209. 12. Hirschberg J. The History of Ophthalmology. Vol 4. Blodi F, trans. Bonn, Germany: JP Wayenborgh; 1984. 13. Ishibashi C. Zum Gedaechtnis von Engelbert Kaempfer und Philipp Franz von Siebold. Kaempfer-Siebold Gedenkfeier: Internationale Medizinische Gesellschaft. Tokyo, Japan: Nippon Kokusai Igaku Kyokai; 1966: 1-6. A Established by HPLC; experimental conditions were as described in "Materials and Methods." b Values are given in % of extract. c Not detected and emtricitabine. Helminths, intestinal protozoa, and bac teria in Tahiti, French Oceania, 440 Hemoglobin values and their relation to the intensity of hookworm infections in the labor force. Problems in tropical public health among workers at a jute mill. The Office of the VP will oversee key facility objectives that include the timely completion and occupancy of new buildings; space planning and renovations to provide interim classroom space and to meet longer-term teaching, research, administrative and service priorities; the construction of a new 440 -bed undergraduate residence; and the financing and initiation of the General Academic Building and related Fine Arts performance facilities. Increased funding from enrolment growth will be flowed to Facilities Management, Finance, Human Resources, and Security Services to expand service capacity of these units concomitant with the overall growth of the University community and emtriva. Either by application of the vegetative forms in a saline suspension directly to the teeth or by dry spores suspended in diatomaceous earth insufflated upon the surfaces of the teeth. Patients were inoculated approximately every 90 days. Bacterial cultures were taken from the oral cavity at the time of the second examination. Early results showed that the implanted organisms seldom remained in the mouth for more than a few hours. With improved techniques using organisms adapted to thrive in the oral environments and by improving the methods of inoculation and recovery, seven persons retained the organism in the oral cavity more than 30 days, two for as long as 7 months. We now expect every inoculated person to retain the organisms for an average of 30 days. More than 400 persons have received B. brevis inoculations in this and in related projects. No toxic effects have been noted over periods of time up to 15 years.'3! O museums. W e very quickly came t o W have been ablet reach a wider public realize that our endeavourwas not with- through these publications. The written out justification since the publication press, radio and television have relayed o h served i s purpose i the best-informed our concerns, enabling us t reach t e t museums: witness the Metropolitan public opinion which alone can engender n Museum of A t New York where and marked changes i certain practices.W e r n immediately informed us of t are being increasinglya s s e procKhmer head shown i the publication ess by the exhibitions staged by the musen which draw the attention Looting i Angkor w s discovered.W e ums themselves, n a o hope t a it rapidly returned i ht i ofthe public t the questionofendangered f response t the request made by the heritagewhen they put an example o such o heritage on display. Such was the case Cambodian Government. during t e exhibition Valleys o the Niger ; h f They are also designed t inform the o a t market. T w o months after our first r publication, an antique dealer i Paris n returned a Khmer statue. Later, two other objects sold by Sotheby'si Lonn don and N e w York were formally ideiitified, and Cambodia has since made requests f r their return. Despite coo operation by Sotheby's, e regret the w f c their `experts' at ht appear t be so uninformed, and allow a renowned institution t put on sale objects that are o widely known t come from systematic o looting and enbrel. Measured when camera linearity is discussed. The scale. Anaphylactic-like reactions to eloxatin r ; have been reported and may occur within minutes of eloxatin r ; administration and enfuvirtide. PRESCRIPTION DRUG MARKETING ACT Effective Decemer 2, 2006 the FDA began enforcing custodial regulations regarding the shipment of pharmaceutical items. As a result, you will find a PDMA fee on any pharmaceutical purchase from Banyan. More detailed information may be found on our website. In adjuvant settings; and that in November 2004 the FDA approved Eloxatin in adjuvant settings.6 Compl., 15, 26-28. Under such circumstances Defendant was open with the Government regarding its intentions to market Eloxatin in first line and adjuvant settings. Costner, 317, F.3d at 887-88. The court will next consider, arguendo, whether Plaintiff has sufficiently pled the intent requirement of the FCA. In support of Plaintiff's allegation that Defendant fraudulently or falsely promoted Eloxatin to doctors, Plaintiff alleges that Defendant provided its sales representatives with information which was neither published nor complete; that it urged doctors to contact WPS to encourage the broadest Medicare coverage for Eloxatin; that it provided sales representatives with training in off-label data for Eloxatin and gave them computers which included such data; that it told its sales representatives to show doctors the data in the computers if the doctors asked about off-label uses for Eloxatin; that it provided sales representatives with sales goals which were impossible to meet without off-label use; that it encouraged sales representatives to use the Drug Assistance Program "DAP" ; to provide Eloxatin in the event a doctor did not get reimbursement for off-label use; and that it gave sales representatives monographs which contained information on the adjuvant and first line trials for Eloxatin. Further in regard to the intent requirement, Plaintiff merely alleges that data which Defendant provided to doctors was "immature and unreliable" and "immature, unreliable, and misleading." Compl., 15, 34. Also, in an affidavit, Plaintiff states that a trial which and enoxacin. Eloxatin eh-lox-ah-tin ; is an anticancer chemotherapy ; medicine that is used with other anti-cancer medicines called 5-fluorouracil 5-fu ; and leucovorin lv ; : to treat adults with stage iii colon cancer after surgery to remove the tumor to treat adults with advanced colon or rectal cancer colo-rectal cancer and eloxatin. Services a to z drug list drugs by condition drug side effects pill identifier interactions checker news & articles new drug approvals new drug applications fda drug alerts clinical trial results drug image search patient care notes medical encyclopedia medical dictionary medical videos - drug classification community forums for professionals drug imprint codes medical abbreviations veterinary drugs contact us news feeds advertise here recent searches adderall rituxan eloxatin citalopram amphadase ranitidine letairis xifaxan oxytrol boniva viagra propecia lipitor xenical ephedrine ibuprofen prilosec acetaminophen and hydrocodone durahist d detrol atrovent exjade seasonique fentora actiq recently approved pristiq arcalyst xyntha simcor accretropin moxatag tekturna hct intelence recothrom flo-pred more and enoxaparin. The molecular weight is 397.3. Oxaliplatin is slightly soluble in water at 6 mg mL, very slightly soluble in methanol, and practically insoluble in ethanol and acetone. CLINICAL PHARMACOLOGY Mechanism of Action Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions of two adjacent guanines GG ; , adjacent adenine-guanines AG ; , and guanines separated by an intervening nucleotide GNG ; . These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific. Pharmacology In vivo studies have shown antitumor activity of oxaliplatin against colon carcinoma. In combination with 5-fluorouracil 5-FU ; , oxaliplatin exhibits in vitro and in vivo antiproliferative activity greater than either compound alone in several tumor models [HT29 colon ; , GR mammary ; , and L1210 leukemia ; ]. Human Pharmacokinetics The reactive oxaliplatin derivatives are present as a fraction of the unbound platinum in plasma ultrafiltrate. The decline of ultrafilterable platinum levels following oxaliplatin administration is triphasic, characterized by two relatively short distribution phases t1 2; 0.43 hours and t1 2; 16.8 hours ; and a long terminal elimination phase t1 2; 391 hours ; . Pharmacokinetic parameters obtained after a single 2-hour IV infusion of ELOXATIN at a dose of 85 mg m2 expressed as ultrafilterable platinum were Cmax of 0.814 g mL and volume of distribution of 440 L. Interpatient and intrapatient variability in ultrafilterable platinum exposure AUC0-48hr ; assessed over 3 cycles was moderate to low 23% and 6%, respectively ; . A pharmacodynamic relationship between platinum ultrafiltrate levels and clinical safety and effectiveness has not been established. Distribution At the end of a 2-hour infusion of ELOXATIN, approximately 15% of the administered platinum is present in the systemic circulation. The remaining 85% is rapidly distributed into tissues or eliminated in the urine. In patients, plasma protein binding of platinum is irreversible and is greater than 90%. The main binding proteins are albumin and gamma-globulins. Platinum also binds irreversibly and accumulates approximately 2-fold ; in erythrocytes, where it appears to have no relevant activity. No platinum accumulation was observed in plasma ultrafiltrate following 85 mg m2 every two weeks. Metabolism Oxaliplatin undergoes rapid and extensive nonenzymatic biotransformation. There is no evidence of cytochrome P450mediated metabolism in vitro. Up to 17 platinum-containing derivatives have been observed in plasma ultrafiltrate samples from patients, including several cytotoxic species monochloro DACH platinum, dichloro DACH platinum, and monoaquo and diaquo DACH platinum ; and a number of noncytotoxic, conjugated species. Elimination The major route of platinum elimination is renal excretion. At five days after a single 2-hour infusion of ELOXATIN, urinary elimination accounted for about 54% of the platinum eliminated, with fecal excretion accounting for only about 2%. Platinum was cleared from plasma at a rate 10 17 L that was similar to or exceeded the average human glomerular filtration rate GFR; 7.5 L h ; . There was no significant effect of gender on the clearance of ultrafilterable platinum. The renal clearance of ultrafilterable platinum is significantly correlated with GFR see ADVERSE REACTIONS ; . Pharmacokinetics in Special Populations Renal Impairment The AUC0-48hr of platinum in the plasma ultrafiltrate increases as renal function decreases. The AUC0-48hr of platinum in patients with mild creatinine clearance, CLcr 50 to 80 min ; , moderate CLcr 30 to 50 min ; and severe renal CLcr 30 mL min ; impairment is increased by about 60, 140 and 190%, respectively, compared to patients with normal renal function CLcr 80 mL min ; see PRECAUTIONS and ADVERSE REACTIONS ; . Drug - Drug Interactions No pharmacokinetic interaction between 85 mg m2 of ELOXATIN and infusional 5-FU has been observed in patients treated every 2 weeks, but increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg m2 of ELOXATIN administered every 3 weeks. In vitro, platinum was not displaced from plasma proteins by the following medications: erythromycin, salicylate, sodium valproate, granisetron, and paclitaxel. In vitro, oxaliplatin is not metabolized by, nor does it inhibit, human cytochrome P450 isoenzymes. No P450-mediated drug-drug interactions are therefore anticipated in patients. Since platinum-containing species are eliminated primarily through the kidney, clearance of these products may be decreased by co-administration of potentially nephrotoxic compounds, although this has not been specifically studied. CLINICAL STUDIES Combination Adjuvant Therapy with ELOXATIN and Infusional 5-FU LV in Patients with Stage II or III Colon Cancer An international, multicenter, randomized study compared the efficacy and evaluated the safety of ELOXATIN in combination with an infusional schedule of 5-FU LV to infusional 5-FU LV alone, in patients with stage II Dukes' B2 ; or III Dukes' C ; colon cancer who had undergone complete resection of the primary tumor. The primary objective of the study was to compare the 3-year disease-free survival DFS ; in patients receiving ELOXATIN and infusional 5-FU LV to those receiving 5-FU LV alone. Patients were to be treated for a total of 6 months i.e., 12 cycles ; . A total of 2246 patients were randomized; 1123 patients per study arm. Patients in the study had to be between 18 and 75 years of age, have histologically proven stage II T3-T4, N0, M0; Dukes' B2 ; or III any T, N1-2 M0; Dukes' C ; colon carcinoma with the inferior pole of the tumor above the peritoneal reflection, i.e., 15 cm from the anal margin ; and undergone within 7 weeks prior to randomization ; complete resection of the primary tumor without gross or microscopic evidence of residual disease. Patients had to have had no prior chemotherapy, immunotherapy, or radiotherapy, and have an ECOG performance status of 0, 1, or 2 KPS 60% ; , absolute neutrophil count ANC ; 1.5x109 L, platelets 100x109 L, serum creatinine 1.25 x ULN total bilirubin 2 x ULN, AST ALT 2 x ULN and carcino-embryogenic antigen CEA ; 10 ng mL. Patients with preexisting peripheral neuropathy NCI grade 1 ; were ineligible for this trial. The following table shows the dosing regimens for the two arms of the study. Treatment Arm ELOXATIN + 5-FU LV FOLFOX4 N 1123 ; 5-FU LV N 1123 ; Table 1 Dosing Regimens in Adjuvant Therapy Study Dose Day 1: ELOXATIN: 85 mg m2 2-hour infusion ; + LV: 200 mg m2 2-hour infusion ; , followed by 5-FU: 400 mg m2 bolus ; , 600 mg m2 22-hour infusion ; Day 2: LV: 200 mg m2 2-hour infusion ; , followed by 5-FU: 400 mg m2 bolus ; , 600 mg m2 22-hour infusion ; Day 1: LV: 200 mg m2 2-hour infusion ; , followed by 5-FU: 400 mg m2 bolus ; , 600 mg m2 22-hour infusion ; Day 2: LV: 200 mg m2 2-hour infusion ; , followed by 5-FU: 400 mg m2 bolus ; , 600 mg m2 22-hour infusion ; The following tables show the baseline characteristics and dosing of the patient population entered into this study. The baseline characteristics were well balanced between arms. Regimen q2w 12 cycles. Glycerol levels were elevated during hyperthyroidism, and the concentrations of free fatty acids FFA ; and 3-hydroxybutyrate 3-OHB ; tended to be elevated. Whole body amino acid kinetics Isotopic enrichments reached a plateau at the end of the study period Fig 2 ; . This was assessed based on the observation that when isotopic enrichment values for phenylalanine and tyrosine were plotted against time the ensuing slopes were not different from zero p values between 0.20 and 0.29 ; . In the hyperthyroid state whole body phenylalanine and tyrosine fluxes were increased Table 3 ; , compared to the euthyroid state. Phenylalanine conversion to tyrosine reflecting amino acid degradation ; was increased, and protein synthesis phenylalanine disposal not accounted for by phenylalanine conversion to tyrosine ; was increased and entacapone. Editor's Note: At the 2002 CMSC meeting in Chicago, the VA-SIG cosponsored a symposium on Assistive Technology for MS, which included a presentation by Ms. Ambrosio. She is a PhD student in the Department of Rehabilitation Science and Technology at the University of Pittsburgh, whose focus of research is wheelchair propulsion biomechanics in individuals with MS. Her presentation in Chicago was based on the work of Rory Cooper, PhD, professor of Bioengineering and Mechanical Engineering at the University of Pittsburgh. Dr. Cooper is the author of two books: Rehabilitation Engineering Applied to Mobility and Manipulation, and Wheelchair Selection and Configuration. Reference citations are available on request. Email VA-SIGnature editor to request and emend. |
|
|
Copyright © 2007 by Online.blackapplehost.com Inc.